登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C12H9F3N2O2
化学文摘社编号:
分子量:
270.21
NACRES:
NA.24
PubChem Substance ID:
UNSPSC Code:
41116107
MDL number:
产品名称
来氟米特, European Pharmacopoeia (EP) Reference Standard
InChI
1S/C12H9F3N2O2/c1-7-10(6-16-19-7)11(18)17-9-4-2-8(3-5-9)12(13,14)15/h2-6H,1H3,(H,17,18)
SMILES string
Cc1oncc1C(=O)Nc2ccc(cc2)C(F)(F)F
InChI key
VHOGYURTWQBHIL-UHFFFAOYSA-N
grade
pharmaceutical primary standard
API family
leflunomide
manufacturer/tradename
EDQM
application(s)
pharmaceutical (small molecule)
format
neat
Gene Information
human ... DHODH(1723)
正在寻找类似产品? 访问 产品对比指南
Application
Leflunomide EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.
Other Notes
Sales restrictions may apply.
Packaging
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
signalword
Danger
hcodes
Hazard Classifications
Acute Tox. 3 Oral - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3
target_organs
Respiratory system
存储类别
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
wgk
WGK 1
flash_point_f
Not applicable
flash_point_c
Not applicable
T Adizie et al.
International journal of clinical practice, 66(9), 906-909 (2012-08-18)
Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) are related inflammatory rheumatic conditions affecting adults over the age of 50 years. Both conditions respond to initial glucocorticoid (GC) therapy. However, most patients require 12-36 months of a tapering steroid regime.
Sebastian Unizony et al.
Current opinion in rheumatology, 25(1), 3-9 (2012-11-02)
Recent advancements in the understanding of the pathogenesis of large-vessel vasculitis may broaden our currently limited therapeutic possibilities. This review summarizes the available evidence for new treatment strategies in this spectrum of diseases. Interleukin (IL) 6 appears to be an
Paul A J Russo et al.
The Annals of pharmacotherapy, 47(3), e15-e15 (2013-03-01)
To study the pharmacokinetics and pharmacogenetics of leflunomide and document its efficacy and safety in the treatment of inflammatory arthritis in a patient with end-stage renal disease (ESRD) who was on peritoneal dialysis. Therapy for a 78-year-old man with ESRD
Paul Bird et al.
The Journal of rheumatology, 40(3), 228-235 (2013-01-17)
To assess the safety of treating patients with rheumatoid arthritis with a combination of methotrexate (MTX) and leflunomide (LEF) in comparison to MTX monotherapy, in clinical practice. The Safety of Methotrexate in Combination with Leflunomide in Rheumatoid Arthritis (SMILE) study
Babak Baban et al.
American journal of physiology. Regulatory, integrative and comparative physiology, 303(11), R1136-R1146 (2012-10-27)
The aryl hydrocarbon receptor (AHR) has emerged as a major modulator of inflammatory processes. We tested the hypothesis that AHR activation protects the ischemic-reperfused kidney in association with the suppression of the inflammatory response. Accordingly, male mice were treated with
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持